Real-time Estimate
Cboe BZX
09:49:10 2024-05-09 am EDT
|
5-day change
|
1st Jan Change
|
45.5
USD
|
-0.48%
|
|
-0.42%
|
-23.99%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,735
|
7,175
|
8,357
|
10,938
|
8,317
|
-
|
-
|
Enterprise Value (EV)
1 |
3,233
|
6,446
|
7,855
|
9,959
|
7,389
|
7,482
|
7,111
|
P/E ratio
|
-22
x
|
-34
x
|
-35.7
x
|
-40.9
x
|
-43.6
x
|
-147
x
|
84.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
49.4
x
|
79.9
x
|
71.4
x
|
38.4
x
|
14.3
x
|
7.74
x
|
5.08
x
|
EV / Revenue
|
42.7
x
|
71.8
x
|
67.1
x
|
34.9
x
|
12.7
x
|
6.96
x
|
4.34
x
|
EV / EBITDA
|
-14.6
x
|
-17.9
x
|
-17.7
x
|
-25.4
x
|
-22.9
x
|
-115
x
|
34.5
x
|
EV / FCF
|
-12
x
|
-26.6
x
|
-33.1
x
|
-24.1
x
|
-23.4
x
|
-180
x
|
36.6
x
|
FCF Yield
|
-8.31%
|
-3.76%
|
-3.02%
|
-4.15%
|
-4.28%
|
-0.56%
|
2.73%
|
Price to Book
|
26.7
x
|
30.5
x
|
-
|
17.5
x
|
6.55
x
|
6.32
x
|
4.4
x
|
Nbr of stocks (in thousands)
|
132,638
|
153,946
|
167,403
|
181,789
|
181,911
|
-
|
-
|
Reference price
2 |
28.16
|
46.61
|
49.92
|
60.17
|
45.72
|
45.72
|
45.72
|
Announcement Date
|
3/18/21
|
3/18/22
|
3/30/23
|
3/11/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
75.68
|
89.79
|
117
|
285.1
|
581.7
|
1,074
|
1,638
|
EBITDA
1 |
-220.8
|
-360.6
|
-443.2
|
-392.1
|
-323.1
|
-65.22
|
206.2
|
EBIT
1 |
-229.2
|
-373
|
-455.8
|
-412.6
|
-337.3
|
-102.2
|
223
|
Operating Margin
|
-302.87%
|
-415.44%
|
-389.58%
|
-144.69%
|
-57.98%
|
-9.51%
|
13.62%
|
Earnings before Tax (EBT)
1 |
-307.6
|
-386.2
|
-445.7
|
-520.1
|
-318.7
|
-90.9
|
236.1
|
Net income
1 |
-303.5
|
-386.2
|
-446.3
|
-518.3
|
-317.6
|
-92.85
|
211.8
|
Net margin
|
-401.02%
|
-430.12%
|
-381.48%
|
-181.75%
|
-54.6%
|
-8.64%
|
12.93%
|
EPS
2 |
-1.280
|
-1.370
|
-1.400
|
-1.470
|
-1.048
|
-0.3114
|
0.5412
|
Free Cash Flow
1 |
-268.8
|
-242.4
|
-237
|
-413.4
|
-316.1
|
-41.57
|
194.1
|
FCF margin
|
-355.14%
|
-269.92%
|
-202.57%
|
-144.97%
|
-54.34%
|
-3.87%
|
11.85%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
94.12%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
91.67%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/18/21
|
3/18/22
|
3/30/23
|
3/11/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
16.88
|
39
|
40.83
|
11.97
|
36.34
|
73.33
|
96.01
|
79.46
|
142.7
|
125.1
|
131.7
|
178.7
|
178.9
|
EBITDA
1 |
-82.13
|
-114.2
|
-
|
-116.1
|
-
|
-
|
-53.64
|
-
|
-63.85
|
-120.6
|
-107.9
|
-93.5
|
-77.21
|
EBIT
1 |
-86.77
|
-117.5
|
-76
|
-125.5
|
-106.9
|
-104.3
|
-56.82
|
-141
|
-60.35
|
-87.05
|
-100.8
|
-91.47
|
-87.64
|
Operating Margin
|
-513.98%
|
-301.22%
|
-186.16%
|
-1,048.6%
|
-294.09%
|
-142.25%
|
-59.18%
|
-177.43%
|
-42.3%
|
-69.59%
|
-76.51%
|
-51.19%
|
-48.98%
|
Earnings before Tax (EBT)
1 |
-124.8
|
-88.33
|
-41.09
|
-193.1
|
-112
|
-198.8
|
-62.5
|
-146.8
|
-66.65
|
-85.52
|
-95.97
|
-83.57
|
-91.64
|
Net income
1 |
-124.8
|
-88.33
|
-41.09
|
-193.2
|
-112.1
|
-199.1
|
-62.21
|
-144.8
|
-66.38
|
-85.29
|
-95.55
|
-82.67
|
-91.79
|
Net margin
|
-738.96%
|
-226.53%
|
-100.64%
|
-1,614.13%
|
-308.51%
|
-271.55%
|
-64.79%
|
-182.24%
|
-46.52%
|
-68.19%
|
-72.53%
|
-46.26%
|
-51.3%
|
EPS
2 |
-0.4300
|
-0.3000
|
-0.1300
|
-0.6200
|
-0.3400
|
-0.5700
|
-0.1700
|
-0.4000
|
-0.1791
|
-0.2805
|
-0.2926
|
-0.2364
|
-0.2475
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/16/21
|
3/18/22
|
6/1/22
|
2/17/23
|
5/18/23
|
8/15/23
|
11/20/23
|
3/11/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
502
|
729
|
501
|
979
|
928
|
835
|
1,206
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-269
|
-242
|
-237
|
-413
|
-316
|
-41.6
|
194
|
ROE (net income / shareholders' equity)
|
-284%
|
-103%
|
-59.1%
|
-51.9%
|
-33.3%
|
-5.72%
|
14%
|
ROA (Net income/ Total Assets)
|
-44.3%
|
-42%
|
-36.4%
|
-32.6%
|
-27.3%
|
-3.18%
|
11.1%
|
Assets
1 |
684.9
|
919.7
|
1,225
|
1,590
|
1,162
|
2,924
|
1,900
|
Book Value Per Share
2 |
1.050
|
1.530
|
-
|
3.440
|
6.980
|
7.230
|
10.40
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
45.7
|
43.9
|
35.7
|
20.1
|
42.2
|
42.3
|
36.1
|
Capex / Sales
|
60.45%
|
48.9%
|
30.54%
|
7.04%
|
7.25%
|
3.93%
|
2.2%
|
Announcement Date
|
3/18/21
|
3/18/22
|
3/30/23
|
3/11/24
|
-
|
-
|
-
|
Last Close Price
45.72
USD Average target price
86.28
USD Spread / Average Target +88.72% Consensus |
1st Jan change
|
Capi.
|
---|
| -24.02% | 8.32B | | +2.93% | 108B | | -2.56% | 23.46B | | -14.60% | 21.72B | | -7.05% | 18.64B | | -38.55% | 17.45B | | -8.83% | 17.19B | | +5.51% | 13.99B | | +37.49% | 12.53B | | +329.39% | 8.81B |
Bio Therapeutic Drugs
|